Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hematological Malignancy: early-phase trial registry
6 of 10 indexed Hematological Malignancy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 6 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Hematological Malignancy: 10 US clinical trials tracked, 6 recruiting.
Hematological Malignancy is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is West Virginia University, running 2 of these trials.
Enrollment posture brief
Registry condition hematological-malignancy
OPEN 6 | RECR 60% | LATE 0 | EARLY 5 | RANK #1724 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abuse, Drug (60% recruiting · 5 trials)
Hematological Malignancy lists 6 open slots (60% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hematological Malignancy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hematological Malignancy is recruiting above its size-band peers.
6 of 10 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hematological Malignancy research.
West Virginia University accounts for 2 of 10 trials (20%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Hematological Malignancy trials plan to enrol fewer than 100 people.
Median target enrolment is 55 among the 10 trials that report a genuine target (sentinel values excluded). 7 of those (70%) plan for fewer than 100 participants.
-
Hematological Malignancy splits between interventional and observational designs.
5 interventional and 5 observational studies make up this index (50% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
Century Therapeutics
NCT05768269
A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
Inova Health Care Services
NCT06106360
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
M.D. Anderson Cancer Center
NCT05110742
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
West Virginia University
NCT05537896
Membrane Target Detection for Leukemia Treatment
University of Missouri-Columbia
NCT04841447
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
Henry Ford Health System
NCT03850366
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Sanofi
NCT01084252
A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)
Merck Sharp & Dohme
NCT06586671
Effect of Body Mass on Filgrastim Pharmacokinetics
Aaron Cumpston, PharmD, BCOP
NCT01719432
Effect of Body Mass on Acyclovir Pharmacokinetics
West Virginia University
NCT01714180
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Hematological Malignancy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hematological Malignancy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hematological Malignancy page
10 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Hematological Malignancy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- West Virginia University sponsors the most Hematological Malignancy trials on record, review their full trial history before evaluating a specific study. See West Virginia University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hematological Malignancy condition card totals 10 registered trials; most-linked intervention Isatuximab SAR650984; top US site state West Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.